ADC Therapeutics SA Profit Loss Attributable To Owners Of Parent
ADC Therapeutics SA (ADCT) reported Profit Loss Attributable To Owners Of Parent of -$155.80 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-03-15.
Discontinued › Notes
ifrs-full:ProfitLossAttributableToOwnersOfParent · last filed 2023-11-07
- ADC Therapeutics SA profit loss attributable to owners of parent for the quarter ending 2022-12-31 was -$24.16M.
- ADC Therapeutics SA profit loss attributable to owners of parent for the quarter ending 2022-09-30 was -$50.61M.
- ADC Therapeutics SA profit loss attributable to owners of parent for the quarter ending 2022-06-30 was -$64.37M.
- ADC Therapeutics SA profit loss attributable to owners of parent for the quarter ending 2022-03-31 was -$16.66M.
| Period end | Profit Loss Attributable To Owners Of Parent 3 month | Profit Loss Attributable To Owners Of Parent 6 month | Profit Loss Attributable To Owners Of Parent 9 month | Profit Loss Attributable To Owners Of Parent 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$24.16M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$74.77M derived: sum of 2 quarters · filed 2023-11-07 | -$139.14M derived: sum of 3 quarters · filed 2023-11-07 | -$155.80M 20-F · filed 2023-03-15 |
| 2022-09-30 | -$50.61M 6-K · filed 2023-11-07 | -$114.98M derived: sum of 2 quarters · filed 2023-11-07 | -$131.64M 6-K · filed 2023-11-07 | -$166.02M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$64.37M 6-K · filed 2023-08-08 | -$81.03M 6-K · filed 2023-08-08 | -$115.42M derived: sum of 3 quarters · filed 2023-08-08 | -$186.97M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$16.66M 6-K · filed 2023-05-09 | -$51.04M derived: sum of 2 quarters · filed 2023-05-09 | -$122.59M derived: sum of 3 quarters · filed 2023-05-09 | -$195.16M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$34.38M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$105.93M derived: sum of 2 quarters · filed 2023-03-15 | -$178.50M derived: sum of 3 quarters · filed 2023-03-15 | -$230.03M 20-F · filed 2023-03-15 |
| 2021-09-30 | -$71.55M 6-K · filed 2022-11-08 | -$144.12M derived: sum of 2 quarters · filed 2022-11-08 | -$195.65M 6-K · filed 2022-11-08 | -$251.57M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$72.57M 6-K · filed 2022-08-09 | -$124.10M 6-K · filed 2022-08-09 | -$180.03M derived: sum of 3 quarters · filed 2023-03-15 | -$200.35M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$51.53M 6-K · filed 2022-05-09 | -$107.46M derived: sum of 2 quarters · filed 2023-03-15 | -$127.78M derived: sum of 3 quarters · filed 2023-03-15 | -$254.34M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$55.93M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$76.26M derived: sum of 2 quarters · filed 2023-03-15 | -$202.81M derived: sum of 3 quarters · filed 2023-03-15 | -$246.29M 20-F · filed 2023-03-15 |
| 2020-09-30 | -$20.33M 6-K · filed 2021-11-02 | -$146.88M derived: sum of 2 quarters · filed 2021-11-02 | -$190.36M 6-K · filed 2021-11-02 | |
| 2020-06-30 | -$126.56M 6-K · filed 2021-08-03 | -$170.03M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$43.48M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | -$116.48M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$123.10M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |